EdgarLookup

Blue Bird Corp — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Blue Bird Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
8.6%
Profit Margin
Net income ÷ revenue
20.4%
Return on Assets
Net income ÷ assets
0.03x
Debt-to-Equity
Total liabilities ÷ equity
+9.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $1.48B Nov 24, 2025
FY2025 Sep 28, 2024 $1.35B Nov 24, 2025
FY2023 Sep 30, 2023 $1.13B Dec 11, 2023
FY2023 Oct 1, 2022 $800.64M Dec 11, 2023
FY2024 Sep 30, 2022 $800.64M Nov 25, 2024
FY2023 Oct 2, 2021 $684.00M Dec 11, 2023
FY2022 Oct 3, 2020 $879.22M Dec 12, 2022
FY2021 Sep 28, 2019 $1.02B Dec 15, 2021
FY2020 Sep 29, 2018 $1.02B Dec 17, 2020
FY2019 Sep 30, 2017 $990.60M Dec 12, 2019

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $1.48B Nov 24, 2025
FY2025 Sep 28, 2024 $1.35B Nov 24, 2025
FY2023 Sep 30, 2023 $1.13B Dec 11, 2023
FY2023 Oct 1, 2022 $800.64M Dec 11, 2023
FY2024 Sep 30, 2022 $800.64M Nov 25, 2024
FY2023 Oct 2, 2021 $684.00M Dec 11, 2023
FY2022 Oct 3, 2020 $879.22M Dec 12, 2022
FY2021 Sep 28, 2019 $1.02B Dec 15, 2021
FY2020 Sep 29, 2018 $1.02B Dec 17, 2020
FY2019 Sep 30, 2017 $990.60M Dec 12, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2015 Oct 3, 2015 $307.62M Dec 15, 2015
FY2015 Jul 4, 2015 $262.65M Dec 15, 2015
FY2015 Apr 4, 2015 $183.02M Dec 15, 2015
FY2015 Jan 3, 2015 $165.83M Dec 15, 2015
FY2015 Sep 27, 2014 $273.74M Dec 15, 2015
FY2015 Jun 28, 2014 $240.33M Dec 15, 2015
FY2015 Mar 29, 2014 $195.67M Dec 15, 2015
FY2015 Dec 28, 2013 $145.99M Dec 15, 2015

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $303.51M Nov 24, 2025
FY2025 Sep 28, 2024 $256.16M Nov 24, 2025
FY2023 Sep 30, 2023 $138.85M Dec 11, 2023
FY2023 Oct 1, 2022 $36.55M Dec 11, 2023
FY2024 Sep 30, 2022 $36.55M Nov 25, 2024
FY2023 Oct 2, 2021 $72.14M Dec 11, 2023
FY2022 Oct 3, 2020 $96.20M Dec 12, 2022
FY2021 Sep 28, 2019 $133.47M Dec 15, 2021
FY2020 Sep 29, 2018 $121.99M Dec 17, 2020
FY2019 Sep 30, 2017 $127.37M Dec 12, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $127.72M Nov 24, 2025
FY2025 Sep 28, 2024 $105.55M Nov 24, 2025
FY2023 Sep 30, 2023 $23.81M Dec 11, 2023
FY2023 Oct 1, 2022 ($45.76M) Dec 11, 2023
FY2024 Sep 30, 2022 ($45.76M) Nov 25, 2024
FY2023 Oct 2, 2021 ($289.0K) Dec 11, 2023
FY2022 Oct 3, 2020 $12.19M Dec 12, 2022
FY2021 Sep 28, 2019 $24.30M Dec 15, 2021
FY2020 Sep 29, 2018 $30.82M Dec 17, 2020
FY2019 Sep 30, 2017 $28.80M Dec 12, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $167.17M Nov 24, 2025
FY2025 Sep 28, 2024 $139.33M Nov 24, 2025
FY2023 Sep 30, 2023 $51.66M Dec 11, 2023
FY2023 Oct 1, 2022 ($40.70M) Dec 11, 2023
FY2024 Sep 30, 2022 ($40.70M) Nov 25, 2024
FY2023 Oct 2, 2021 $6.52M Dec 11, 2023
FY2022 Oct 3, 2020 $21.99M Dec 12, 2022
FY2021 Sep 28, 2019 $43.83M Dec 15, 2021
FY2020 Sep 29, 2018 $35.08M Dec 17, 2020
FY2019 Sep 30, 2017 $59.53M Dec 12, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $15.20M Nov 24, 2025
FY2025 Sep 28, 2024 $9.40M Nov 24, 2025
FY2023 Sep 30, 2023 $6.60M Dec 11, 2023
FY2023 Oct 1, 2022 $6.10M Dec 11, 2023
FY2024 Sep 30, 2022 $6.10M Nov 25, 2024
FY2023 Oct 2, 2021 $5.20M Dec 11, 2023
FY2022 Oct 3, 2020 $6.40M Dec 12, 2022
FY2021 Sep 28, 2019 $11.50M Dec 15, 2021
FY2020 Sep 29, 2018 $8.50M Dec 17, 2020
FY2019 Sep 30, 2017 $7.40M Dec 12, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $136.35M Nov 24, 2025
FY2025 Sep 28, 2024 $116.83M Nov 24, 2025
FY2023 Sep 30, 2023 $87.19M Dec 11, 2023
FY2023 Oct 1, 2022 $77.25M Dec 11, 2023
FY2024 Sep 30, 2022 $77.25M Nov 25, 2024
FY2023 Oct 2, 2021 $65.62M Dec 11, 2023
FY2022 Oct 3, 2020 $74.21M Dec 12, 2022
FY2021 Sep 28, 2019 $89.64M Dec 15, 2021
FY2020 Sep 29, 2018 $86.91M Dec 17, 2020
FY2019 Sep 30, 2017 $67.84M Dec 12, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $176.21M Nov 24, 2025
FY2025 Sep 28, 2024 $111.11M Nov 24, 2025
FY2023 Sep 30, 2023 $119.93M Dec 11, 2023
FY2023 Oct 1, 2022 ($24.44M) Dec 11, 2023
FY2024 Sep 30, 2022 ($24.44M) Nov 25, 2024
FY2023 Oct 2, 2021 ($54.24M) Dec 11, 2023
FY2022 Oct 3, 2020 $3.46M Dec 12, 2022
FY2021 Sep 28, 2019 $55.71M Dec 15, 2021
FY2020 Sep 29, 2018 $48.35M Dec 17, 2020
FY2019 Sep 30, 2017 $47.64M Dec 12, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $625.26M Nov 24, 2025
FY2025 Sep 28, 2024 $524.89M Nov 24, 2025
FY2024 Sep 30, 2023 $417.77M Nov 25, 2024
FY2023 Oct 1, 2022 $366.13M Dec 11, 2023
FY2022 Oct 2, 2021 $356.02M Dec 12, 2022
FY2021 Oct 3, 2020 $317.42M Dec 15, 2021
FY2020 Sep 28, 2019 $365.41M Dec 17, 2020
FY2019 Sep 29, 2018 $307.43M Dec 12, 2019
FY2018 Sep 30, 2017 $295.82M Dec 12, 2018
FY2017 Oct 1, 2016 $277.87M Dec 8, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2014 Dec 31, 2014 $8.41M Feb 27, 2015
FY2014 Dec 31, 2013 $323.0K Feb 27, 2015

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $255.42M Nov 24, 2025
FY2025 Sep 28, 2024 $159.56M Nov 24, 2025
FY2024 Sep 30, 2023 $40.00M Nov 25, 2024
FY2023 Oct 1, 2022 $1.38M Dec 11, 2023
FY2022 Oct 2, 2021 ($32.66M) Dec 12, 2022
FY2021 Oct 3, 2020 ($53.23M) Dec 15, 2021
FY2020 Sep 28, 2019 ($67.81M) Dec 17, 2020
FY2019 Sep 29, 2018 ($28.34M) Dec 12, 2019
FY2018 Sep 30, 2017 ($58.51M) Dec 12, 2018
FY2017 Oct 1, 2016 ($86.97M) Dec 8, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $18.83M Nov 24, 2025
FY2025 Sep 28, 2024 $18.83M Nov 24, 2025
FY2024 Sep 30, 2023 $18.83M Nov 25, 2024
FY2023 Oct 1, 2022 $18.83M Dec 11, 2023
FY2022 Oct 2, 2021 $18.83M Dec 12, 2022
FY2021 Oct 3, 2020 $18.83M Dec 15, 2021
FY2020 Sep 28, 2019 $18.83M Dec 17, 2020
FY2019 Sep 29, 2018 $18.83M Dec 12, 2019
FY2018 Sep 30, 2017 $18.83M Dec 12, 2018
FY2017 Oct 1, 2016 $18.83M Dec 8, 2017

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $88.19M Nov 24, 2025
FY2025 Sep 28, 2024 $0 Nov 24, 2025
FY2024 Sep 30, 2023 ($55.70M) Nov 25, 2024
FY2023 Oct 1, 2022 ($79.51M) Dec 11, 2023
FY2022 Oct 2, 2021 ($33.75M) Dec 12, 2022
FY2021 Oct 3, 2020 ($33.46M) Dec 15, 2021
FY2020 Sep 28, 2019 ($45.65M) Dec 17, 2020
FY2019 Sep 29, 2018 ($69.24M) Dec 12, 2019
FY2018 Sep 30, 2017 ($100.06M) Dec 12, 2018
FY2017 Oct 1, 2016 ($128.86M) Dec 8, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 $229.31M Nov 24, 2025
FY2025 Sep 28, 2024 $127.69M Nov 24, 2025
FY2024 Sep 30, 2023 $78.99M Nov 25, 2024
FY2023 Oct 1, 2022 $10.48M Dec 11, 2023
FY2022 Oct 2, 2021 $11.71M Dec 12, 2022
FY2021 Oct 3, 2020 $44.51M Dec 15, 2021
FY2020 Sep 28, 2019 $70.96M Dec 17, 2020
FY2019 Sep 29, 2018 $60.26M Dec 12, 2019
FY2019 Sep 30, 2017 $62.62M Dec 12, 2019
FY2018 Oct 1, 2016 $52.31M Dec 12, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 4 Nov 24, 2025
FY2025 Sep 28, 2024 3 Nov 24, 2025
FY2023 Sep 30, 2023 0 Dec 11, 2023
FY2023 Oct 1, 2022 (1) Dec 11, 2023
FY2024 Sep 30, 2022 (1) Nov 25, 2024
FY2023 Oct 2, 2021 0 Dec 11, 2023
FY2022 Oct 3, 2020 0 Dec 12, 2022
FY2021 Sep 28, 2019 0 Dec 15, 2021
FY2020 Sep 29, 2018 1 Dec 17, 2020
FY2019 Sep 30, 2017 0 Dec 12, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 3 Nov 24, 2025
FY2025 Sep 28, 2024 3 Nov 24, 2025
FY2023 Sep 30, 2023 0 Dec 11, 2023
FY2023 Oct 1, 2022 (1) Dec 11, 2023
FY2024 Sep 30, 2022 (1) Nov 25, 2024
FY2023 Oct 2, 2021 0 Dec 11, 2023
FY2022 Oct 3, 2020 0 Dec 12, 2022
FY2021 Sep 28, 2019 0 Dec 15, 2021
FY2020 Sep 29, 2018 1 Dec 17, 2020
FY2019 Sep 30, 2017 0 Dec 12, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Sep 27, 2025 31.88M Nov 24, 2025
FY2025 Sep 28, 2024 32.27M Nov 24, 2025
FY2024 Sep 30, 2023 32.17M Nov 25, 2024
FY2023 Oct 1, 2022 32.02M Dec 11, 2023
FY2022 Oct 2, 2021 27.21M Dec 12, 2022
FY2021 Oct 3, 2020 27.05M Dec 15, 2021
FY2020 Sep 28, 2019 26.48M Dec 17, 2020
FY2019 Sep 29, 2018 27.26M Dec 12, 2019
FY2018 Sep 30, 2017 23.74M Dec 12, 2018
FY2017 Oct 1, 2016 22.52M Dec 8, 2017